Imaging of delta opioid receptors in human brain by N1'-([ super(11)C]methyl)naltrindole and PET

• Published in: Synapse (New York, N.Y.) Vol. 24; no. 1; pp. 19 - 28
• Main Authors: Madar, I, Lever, J R, Kinter, C M, Scheffel, U, Ravert, H T, Musachio, J L, Mathews, W B, Dannals, R F, Frost, J J
• Format: Journal Article
• Language: English
• Published: 01-09-1996
• ISSN: 0887-4476

Recently, we have developed the positron emitting radiotracer N1'-([ super(11)C]methyl)naltrindole ([ super(11)C]MeNTI) and demonstrated its high selectivity for delta opioid receptors in the mouse brain. In the present study, we examined the selectivity of [ super(11)C]MeNTI for the delta opioid receptor in the human brain, using positron emission tomography (PET). The regional kinetics and distribution as well as the pharmacology confirmed the selectivity of [ super(11)C]MeNTI for delta opioid receptor in the human brain. First, the regional kinetics of [ super(11)C]MeNTI are in accordance with the density of the delta opioid receptor. Rapid washout in receptor-poor areas and prolonged retention in receptor-rich areas were observed. Second, the regional distribution of [ super(11)C]MeNTI correlated well (r = 0.91) with the in vitro distribution of delta opioid sites but not with mu or Kappa site densities (r less than or equal to 0.008 or r less than or equal to 0.014, respectively). [ super(11)C]MeNTI binding was highest in regions of the neocortex (insular, parietal, frontal, cingulate, and occipital), caudate nucleus, and putamen. Binding was intermediate in the amygdala and lowest in the cerebellum and thalamus. Third, studies using the competitive antagonist naltrexone demonstrated the inhibition of [ super(11)C]MeNTI binding. Naltrexone inhibition of [ super(11)C]MeNTI binding was most effective in delta receptor-rich regions, and its inhibitory potency correlated well (r = 0.88) with the regional distribution of delta opioid sites. [ super(11)C]MeNTI is the first radioligand which selectively labels delta opioid receptors in vivo in the human brain following systemic administration. The availability of [ super(11)C]MeNTI will enable a receptor specific analysis of the role of [ super(11)C]MeNTI receptors in normal and abnormal human brain.